Uveitis Study Needs Participants

Patients, both male and female, between the ages of 18 and 25, with non-infectious acute anterior uveitis and any previous episodes of acute anterior ileitis occurring at least four weeks before starting the study are being invited to enroll in a safety and efficacy study of iontophoresis and dexamethasone phosphate to treat anterior uveitis.  The study is being sponsored by EyeGate Pharmaceutical. 

This is a randomized, double-masked exploratory study of four doses of iontophoretic delivery of dexamethasone phosphate ophthalmic solution in patients with non-infectious acute anterior segment uveitis. The current study will evaluate the safety, tolerability, and efficacy of the technology at the four dose levels to determine a safe, effective dose that is appropriate for future trials.

Five centers currently enrolling patients are located in Cambridge and Boston, MA; New York, NY; Norfolk, VA; and Columbus, OH.

For more information or to enroll, go to www.clinicaltrials.gov  (study#NCT00694135); or contact Debbie Chmielewski at 887-334-0050 (a Texas number) or e-mail debbiechmielewski@pleiad.com.

 Source: EyeGate Pharmaceuticals, Waltham, MA

Autoimmune Diseases Association, InFocus, Vol. 16 No. 3, September 2008